2XP2
Structure of the Human Anaplastic Lymphoma Kinase in Complex with Crizotinib (PF-02341066)
Summary for 2XP2
Entry DOI | 10.2210/pdb2xp2/pdb |
Descriptor | TYROSINE-PROTEIN KINASE RECEPTOR, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine (3 entities in total) |
Functional Keywords | crizotinib, transferase |
Biological source | HOMO SAPIENS (HUMAN) |
Total number of polymer chains | 1 |
Total formula weight | 37359.69 |
Authors | McTigue, M.,Deng, Y.,Liu, W.,Brooun, A.,Timofeevski, S.,Marrone, T.,Cui, J.J. (deposition date: 2010-08-24, release date: 2010-09-15, Last modification date: 2023-12-20) |
Primary citation | Cui, J.J.,Tran-Dube, M.,Shen, H.,Nambu, M.,Kung, P.P.,Pairish, M.,Jia, L.,Meng, J.,Funk, L.,Botrous, I.,Mctigue, M.,Grodsky, N.,Ryan, K.,Padrique, E.,Alton, G.,Timofeevski, S.,Yamazaki, S.,Li, Q.,Zou, H.,Christensen, J.,Mroczkowski, B.,Bender, S.,Kania, R.S.,Edwards, M.P. Structure Based Drug Design of Crizotinib (Pf-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (C-met) Kinase and Anaplastic Lymphoma Kinase (Alk). J.Med.Chem, 54:6342-, 2011 Cited by PubMed: 21812414DOI: 10.1021/JM2007613 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.9 Å) |
Structure validation
Download full validation report